Thromboembolic events in brain tumour patients on bevacizumab

Figures & data

Table 1. Khorana score.

Parameters	Number	Percentage (%)
Pre-bevacizumab haemoglobin <10 g/dL or using RBC growth factors
Yes	5	6.3
No	75	93.7
Pre-bevacizumab platelet count ≥350 × 10^9/L
Yes	3	3.8
No	77	96.3
Pre- bevacizumab leukocyte count >11 × 10^9/L
Yes	09	11.3
No	71	88.7
Body mass index (BMI) ≥35 kg/m²
Yes	25	31.3
No	55	68.7
Khorana score
0	43	53.8
1	33	41.3
2	4	5
3	0	0

Table 2. Khorana score and VTE.

Khorana score	Venous thromboembolism (VTE)
	Yes	No
0	2 (4.7%)	41 (95.3%)
1	4 (12.1%)	29 (87.9%)
2	1 (25%)	3 (75%)
3	0	0

Data availability statement

The authors confirm that the data supporting the findings of this study are available within the article.